Search results for "Pyridine"

showing 10 items of 2516 documents

Sorafenib in advanced hepatocellular carcinoma

2008

none 25 BACKGROUND: No effective systemic therapy exists for patients with advanced hepatocellular carcinoma. A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma. METHODS: In this multicenter, phase 3, double-blind, placebo-controlled trial, we randomly assigned 602 patients with advanced hepatocellular carcinoma who had not received previous systemic treatment to receive either sorafenib (at a dose of 400 mg twice daily) or placebo. Primary outcomes were overall survival and the time to symptomatic progression. Seconda…

SorafenibMaleNiacinamidemedicine.medical_specialtyCarcinoma HepatocellularPyridinesPlaceboGastroenterologyDouble-Blind MethodInternal medicinemedicineCarcinomaHumansHEPATOCELLULAR CARCINOMAProtein Kinase InhibitorsAgedNeoplasm StagingProportional Hazards Modelsbusiness.industryPhenylurea CompoundsHazard ratioBenzenesulfonatesLiver NeoplasmsGeneral MedicineTREATMENTMiddle AgedSorafenibmedicine.diseaseInterim analysisSurvival AnalysisRecurrent Hepatocellular Carcinomadigestive system diseasesSurgeryHEPATOCELLULAR CARCINOMA; SORAFENIB; TREATMENTChemotherapy AdjuvantHepatocellular carcinomaDisease ProgressionFemaleraf KinasesbusinessLiver cancermedicine.drug
researchProduct

Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy

2011

A multicenter randomized controlled trial established sorafenib as a standard of care for patients with advanced hepatocellular carcinoma (HCC). Because the study was prematurely interrupted due to survival benefits in the sorafenib arm, we conducted an observational study to adequately assess risks and benefits of this regimen in field practice. Starting in 2008, all clinically compensated patients with advanced HCC and those with an intermediate HCC who were unfit or failed to respond to ablative therapies were consecutively evaluated in six liver centers in Italy, for tolerability as well as radiologic and survival response to 800-mg/d sorafenib therapy. Treatment was down-dosed or inter…

SorafenibNiacinamideMalemedicine.medical_specialtyCarcinoma HepatocellularDrug-Related Side Effects and Adverse ReactionsPyridinesAntineoplastic AgentsEPATOCARCINOMAlaw.inventionRandomized controlled triallawDrug ToxicityInternal medicinemedicineHumansProspective StudiesHCCProspective cohort studySurvival analysisAgedHCC; sorafenibHepatologybusiness.industryPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsCarcinomaSettore MED/09 - MEDICINA INTERNAHepatocellularSorafenibMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseasesSurgeryHepatocellular carcinoma sorafenibRegimenTUMORI DEL FEGATOTolerabilityItalyHepatocellular carcinomaDisease ProgressionsorafenibFemaleLiver cancerbusinessmedicine.drug
researchProduct

Multimodal approaches to the treatment of hepatocellular carcinoma.

2008

The prevalence of hepatocellular carcinoma in Europe and the US is increasing and is currently the leading cause of death in patients with cirrhosis. Surveillance programs for patients with cirrhosis aim to detect tumors at an early stage, when the greatest therapeutic benefits can be achieved. Curative treatments for early-stage tumors include liver transplantation, resection and percutaneous ablation. Transarterial chemoembolization (TACE) and sorafenib can improve survival for patients with intermediate and advanced tumors, respectively. In clinical practice, combination therapies are often used, despite limited evidence to support this approach from randomized controlled trials. Combina…

SorafenibNiacinamidemedicine.medical_specialtyCarcinoma HepatocellularCombination therapyWaiting ListsRadiofrequency ablationPyridinesmedicine.medical_treatmentSalvage therapyAntineoplastic AgentsLiver transplantationlaw.inventionInjectionslawPreoperative CaremedicineCombined Modality TherapyHumansChemoembolization TherapeuticSalvage TherapyHepatologyEthanolbusiness.industryepatocarcinoma cirrosi HBV HCVPhenylurea CompoundsBenzenesulfonatesLiver NeoplasmsGastroenterologySorafenibmedicine.diseaseCombined Modality TherapyEmbolization TherapeuticSurgeryLiver TransplantationHepatocellular carcinomaCatheter AblationRadiotherapy AdjuvantRadiologyPercutaneous ethanol injectionbusinessmedicine.drugNature clinical practice. Gastroenterologyhepatology
researchProduct

Immune oncology in hepatocellular carcinoma-hype and hope.

2017

SorafenibOncologyNiacinamidemedicine.medical_specialtyCarcinoma HepatocellularPyridinesMEDLINEAntineoplastic AgentsDrug resistance03 medical and health sciences0302 clinical medicineImmune systemInternal medicinemedicineCarcinomaNeoplasmHumans030212 general & internal medicineProtein Kinase Inhibitorsbusiness.industryPhenylurea CompoundsLiver NeoplasmsGeneral MedicineSorafenibmedicine.diseaseDrug Resistance NeoplasmHepatocellular carcinoma030211 gastroenterology & hepatologybusinessmedicine.drugLancet (London, England)
researchProduct

Poly(ethylene glycol) diacrylate-based solid-phase extraction for determination of sulfonamides in meat samples

2020

Abstract In this work, a sorbent based on poly(ethylene glycol) diacrylate (PEGDA) polymer has been synthesized for solid-phase extraction (SPE) of sulfonamides (sulfaguanidine, sulfadiazine, sulfathiazole, sulfapyridine, sulfamethazine, sulfamonomethoxine, sulfamethoxazole, sulfisoxazole) from different meat matrices, which were subsequently determined by HPLC-DAD. Several extraction parameters such as loading and elution solvents as well as other variables (loading capacity, breakthrough volume and reusability) influencing on the analytical performance of the sorbent were optimized. Under the optimal conditions, the developed method was successfully applied to determine the eight sulfonam…

SorbentChromatographyChemistryElution010401 analytical chemistryExtraction (chemistry)02 engineering and technologySulfapyridine021001 nanoscience & nanotechnology01 natural sciences0104 chemical sciencesAnalytical Chemistrychemistry.chemical_compoundmedicineSulfamonomethoxineSolid phase extraction0210 nano-technologySulfaguanidineEthylene glycolSpectroscopymedicine.drugMicrochemical Journal
researchProduct

CCDC 1422372: Experimental Crystal Structure Determination

2016

Related Article: Sarah Keller, Antonio Pertegás, Giulia Longo, Laura Martínez, Jesús Cerdá, José M. Junquera-Hernández, Alessandro Prescimone, Edwin C. Constable, Catherine E. Housecroft, Enrique Ortí, Henk J. Bolink|2016|J.Mater.Chem.C|4|3857|doi:10.1039/C5TC03725E

Space GroupCrystallography((99-Dimethyl-9H-xanthene-45-diyl)bis(diphenylphosphine))-(6-methyl-22'-bipyridine)-copper(i) hexafluorophosphate dichloromethane diethyl ether solvateCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 2081394: Experimental Crystal Structure Determination

2021

Related Article: Marco Meyer, Lorenzo Mardegan, Daniel Tordera, Alessandro Prescimone, Michele Sessolo, Henk J. Bolink, Edwin C. Constable, Catherine E. Housecroft|2021|Dalton Trans.|50|17920|doi:10.1039/D1DT03239A

Space GroupCrystallography((99-Dimethyl-9H-xanthene-45-diyl)bis(diphenylphosphine))-(6-methyl-22'-bipyridine)-copper(i) hexafluorophosphate dichloromethane diethyl ether solvateCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 1581155: Experimental Crystal Structure Determination

2018

Related Article: Sarah Keller, Fabian Brunner, José M. Junquera‐Hernández, Antonio Pertegás, Maria‐Grazia La‐Placa, Alessandro Prescimone, Edwin C. Constable, Henk J. Bolink, Enrique Ortí, Catherine E. Housecroft|2018|ChemPlusChem|83|217|doi:10.1002/cplu.201700501

Space GroupCrystallography((99-dimethyl-9H-xanthene-45-diyl)bis(diphenylphosphine))-(6-(trifluoromethyl)-22'-bipyridine)-copper(i) hexafluorophosphate dichloromethane diethyl ether solvateCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 1407134: Experimental Crystal Structure Determination

2015

Related Article: Marcel Dommaschk, Vanessa Thoms, Christian Schütt, Christian Näther, Rakesh Puttreddy, Kari Rissanen, and Rainer Herges|2015|Inorg.Chem.|54|9390|doi:10.1021/acs.inorgchem.5b01756

Space GroupCrystallography(1124-dimethyl-271520-tetrakis(pentafluorophenyl)-112427282930-hexaazaheptacyclo[19.5.1.136.1814.11619.0913.02226]triaconta-1(27)246(30)714(29)151719(28)20-decaene)-bis(pyridine)-nickel pyridine solvateCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 837872: Experimental Crystal Structure Determination

2013

Related Article: B.Macias, M.V.Villa, R.Lapresa, G.Alzuet, J.Hernandez-Gil, F.Sanz|2012|J.Inorg.Biochem.|115|64|doi:10.1016/j.jinorgbio.2012.05.019

Space GroupCrystallography(22'-Bipyridine)-(bis(N-(quinolin-8-yl)benzenesulfonamidato))-manganese(ii)Crystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct